$13.16
+2.41 (+22.42%)
Open$11.12
Previous Close$10.75
Day High$14.01
Day Low$11.00
52W High$39.75
52W Low$6.27
Volume—
Avg Volume13.3K
Market Cap22.66M
P/E Ratio—
EPS$-18.59
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+74.8% upside
Current
$13.16
$13.16
Target
$23.00
$23.00
$15.62
$23.00 avg
$28.09
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.59M | 3.48M | 3.01M |
| Net Income | 732.2K | 573.7K | 520.4K |
| Profit Margin | 20.4% | 16.5% | 17.3% |
| EBITDA | 1.09M | 1.00M | 849.7K |
| Free Cash Flow | 537.7K | 589.4K | 453.2K |
| Rev Growth | +3.4% | -1.6% | +9.6% |
| Debt/Equity | 0.28 | 0.26 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |